NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
Clinical Trials
12 trialsNCT01946477 2025-06-06
POM MM 014
Celgene
Phase 2 Completed
NCT02506959 2025-03-18
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02184533 2024-05-28
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Stanford University
Phase 1 Completed
NCT02547662 2023-10-30
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Mayo Clinic
Phase 2 Completed
NCT00421525 2021-08-16
Phase I/II Study of hLL1 in Multiple Myeloma
Gilead Sciences
Phase 1/2 Completed
NCT00821249 2020-10-19
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Pfizer
Phase 1/2 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT00569868 2011-08-12
UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma
University of Arkansas
Phase NA Completed
NCT00081757 2010-07-02
An Open Protocol for the Compassionate Use of Thalidomide
University of Arkansas
Phase 1/2 Completed
NCT00988312 2009-10-02
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
University Hospital Carl Gustav Carus
Phase 1 Completed
NCT00781170 2009-05-28
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Completed